Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and/or Septic Shock

ConditionsAIDS Pneumonia Septic Shock

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-65

SponsorGuangzhou 8th People's Hospital

About this trial

Observing the Real-World Application Effectiveness of Cytokine Immune Adsorption Technology in AIDS Patients with Severe Pneumonia or septic shock.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Confirmed HIV infection;

Progression to AIDS stage: CD4+ count <200 cells/ul and/or occurrence of AIDS opportunistic infections;

Age between 18 and 65 years;

The criteria for severe pneumonia diagnosis refer to the 2021 ATS (American Thoracic Society) and IDSA (Infectious Diseases Society of America) guidelines for the treatment of community-acquired pneumonia;

Disqualifiers

Coexisting central nervous system lesions, severe liver disease, or cirrhosis;

Concurrent AIDS-related or unrelated tumors;

Women who are pregnant or breastfeeding;

Severe underlying diseases of the heart, lungs, liver, kidneys, etc.;

Trial population

All study participants come from the OSPWH (Patients With HIV/AIDS) cohort at the Guangzhou Eighth People's Hospital.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Cytokine Adsorption
Device
During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.

Treatment groups

60 Participants

are divided into 2 treatment groups

Group A: Cytokine Adsorption Combined with Standard Treatment Group1 intervention

Group B: Standard Treatment Group0 interventions

Trial outcomes

Primary outcomes

Mortality rate

Compare the mortality rates of the cytokine adsorption combined with standard treatment group and the standard treatment group.

Time frame

4 weeks

Secondary outcomes

Improvement in critical care scoring

Improvements in the intensive care scoring systems SOFA score and APACHE II score from baseline and after intervention.

Time frame

Baseline and during treatment at weeks 1, 2, 3, 4.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Guangzhou 8th People's Hospital

Lead sponsor

Source ClinicalTrials.gov

Apply now